Drug intelligence / Profile preview

GLA-SE adjuvant

Development stage: Phase 1
Lead developer: Access to Advanced Health Institute
Modality: Small Molecules, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

GLA-SE (Glucopyranosyl Lipid A in Stable Emulsion) is a synthetic Toll-like receptor 4 (TLR4) agonist formulated in a stable nano-emulsion of squalene oil. Developed by the Infectious Disease Research Institute (IDRI), it serves as a vaccine adjuvant designed to enhance Th1-type immune responses to co-administered antigens. The active component, glucopyranosyl lipid A (GLA), is a synthetic analog of lipid A. GLA-SE has been investigated in clinical trials for various infectious diseases, including HIV, influenza, leishmaniasis, and schistosomiasis, often in combination with protein subunit vaccines to induce potent antibody and cellular immunity.

Other names: Glucopyranosyl Lipid A in Stable Emulsion

Targets

TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on GLA-SE adjuvant.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GLA-SE adjuvant.

Explore the full profile